Anionic site interactions in human butyrylcholinesterase disrupted by two single point mutations.
Structure-function relationships of recombinant human butyrylcholinesterase (CHE) variants were investigated by Xenopus oocyte microinjection. A Ser-425 to Pro-425 mutation failed to modify ligand binding properties. In contrast, Asp-70 to Gly-70 substitution significantly reduced CHE binding capacity for succinylcholine and specific inhibitors, demonstrating Asp-70 as a key anionic site component for certain ligands. Furthermore, the presence of both mutations rendered CHE totally resistant to succinylcholine and dibucaine inhibition, while all mutant proteins bound butyrylthiocholine, benzoylcholine, and propionylcholine normally. These findings imply structural interactions between the conserved Asp-70 and Ser-425 regions in cholinesterases and suggest the contribution of additional electronegative amino acids to anionic site binding.
Neville
L F
LF
Department of Biological Chemistry, Hebrew University of Jerusalem, Israel.
Gnatt
A
A
Padan
R
R
Seidman
S
S
Soreq
H
H
D000838:Anions; D001665:Binding Sites; D001932:Brain Neoplasms / Q000201:enzymology; D002091:Butyrylcholinesterase / Q000235:genetics* / Q000378:metabolism; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D004273:DNA, Neoplasm / Q000235:genetics; D003992:Dibucaine / Q000494:pharmacology; D014644:Genetic Variation; D005910:Glioma / Q000201:enzymology; D006801:Humans; D016297:Mutagenesis, Site-Directed; D009447:Neuroblastoma / Q000201:enzymology; D011994:Recombinant Proteins / Q000378:metabolism; D013379:Substrate Specificity; D013390:Succinylcholine / Q000494:pharmacology
D000838:Anions; D002800:Cholinesterase Inhibitors; D004273:DNA, Neoplasm; D011994:Recombinant Proteins; D002091:Butyrylcholinesterase; D013390:Succinylcholine; D003992:Dibucaine